Javier Traba

Javier Traba

Auto-generated profile, based on publicly available information

Javier Traba

Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892; and

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MAMunir Akkaya
Munir Akkaya
JTJavier Traba
Javier Traba
ARAlexander S. Roesler
Alexander S. Roesler
PMPietro Miozzo
Pietro Miozzo
BABillur Akkaya
Billur Akkaya
SPSusan K. Pierce
Susan K. Pierce

26 October 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JTJavier Traba
Javier Traba
MKMiriam Kwarteng-Siaw
Miriam Kwarteng-Siaw
TOTracy C. Okoli
Tracy C. Okoli
JLJessica Li
Jessica Li
RHRebecca D. Huffstutler
Rebecca D. Huffstutler
MSMichael N Sack
Michael N Sack
BACKGROUND. Activation of the NLRP3 inflammasome is associated with metabolic dysfunction, and intermittent fasting has been shown to improve clinical presentation of NLRP3 inflammasome–linked diseases. As mitochondrial perturbations, which function as a damage-associated molecular pattern, exacerbate NLRP3 inflammasome activation, we investigated whether fasting blunts inflammasome activation via sirtuin-mediated augmentation of mitochondrial integrity. METHODS. We performed a clinical study of 19 healthy volunteers. Each subject underwent a 24-hour fast and then was fed a fixed-calorie meal. Blood was drawn during the fasted and fed states and analyzed for NRLP3 inflammasome activation. We enrolled an additional group of 8 healthy volunteers to assess the effects of the sirtuin activator, nicotinamide riboside, on NLRP3 inflammasome activation. RESULTS. In the fasting/refeeding study, individuals showed less NLRP3 inflammasome activation in the fasted state compared with that in refed conditions. In a human macrophage line, depletion of the mitochondrial-enriched sirtuin deacetylase SIRT3 increased NLRP3 inflammasome activation in association with excessive mitochondrial ROS production. Furthermore, genetic and pharmacologic SIRT3 activation blunted NLRP3 activity in parallel with enhanced mitochondrial function in cultured cells and in leukocytes extracted from healthy volunteers and from refed individuals but not in those collected during fasting. CONCLUSIONS. Together, our data indicate that nutrient levels regulate the NLRP3 inflammasome, in part through SIRT3-mediated mitochondrial homeostatic control. Moreover, these results suggest that deacetylase-dependent inflammasome attenuation may be amenable to targeting in human disease. TRIAL REGISTRATION. ClinicalTrials.gov NCT02122575 and NCT00442195. FUNDING. Division of Intramural Research, NHLBI of the NIH.

1 July 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JTJavier Traba
Javier Traba
SGSarah S. Geiger
Sarah S. Geiger
MKMiriam Kwarteng-Siaw
Miriam Kwarteng-Siaw
KHKim Han
Kim Han
OROne Hyuk Ra
One Hyuk Ra
MSMichael N Sack
Michael N Sack
Twenty-four hours of fasting is known to blunt activation of the human NLRP3 inflammasome. This effect might be mediated by SIRT3 activation, controlling mitochondrial reactive oxygen species. To characterize the molecular underpinnings of this fasting effect, we comparatively analyzed the NLRP3 inflammasome response to nutrient deprivation in wild-type and SIRT3 knock-out mice. Consistent with previous findings for human NLRP3, prolonged fasting blunted the inflammasome in wild-type mice but not in SIRT3 knock-out mice. In SIRT3 knock-out bone marrow–derived macrophages, NLRP3 activation promoted excess cytosolic extrusion of mitochondrial DNA along with increased reactive oxygen species and reduced superoxide dismutase 2 (SOD2) activity. Interestingly, the negative regulatory effect of SIRT3 on NLRP3 was not due to transcriptional control or priming of canonical inflammasome components but, rather, occurred via SIRT3-mediated deacetylation of mitochondrial SOD2, leading to SOD2 activation. We also found that siRNA knockdown of SIRT3 or SOD2 increased NLRP3 supercomplex formation and activation. Moreover, overexpression of wild-type and constitutively active SOD2 similarly blunted inflammasome assembly and activation, effects that were abrogated by acetylation mimic–modified SOD2. Finally, in vivo administration of lipopolysaccharide increased liver injury and the levels of peritoneal macrophage cytokines, including IL-1β, in SIRT3 KO mice. These results support the emerging concept that enhancing mitochondrial resilience against damage-associated molecular patterns may play a pivotal role in preventing inflammation and that the anti-inflammatory effect of fasting-mimetic diets may be mediated, in part, through SIRT3-directed blunting of NLRP3 inflammasome assembly and activation.

21 October 2011 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
JTJ Traba
J Traba
AAA del Arco
A del Arco
MDM R Duchen
M R Duchen
GSG Szabadkai
G Szabadkai
JSJorgina Satrustegui
Jorgina Satrustegui
Ca2+-mediated mitochondrial permeability transition (mPT) is the final common pathway of stress-induced cell death in many major pathologies, but its regulation in intact cells is poorly understood. Here we report that the mitochondrial carrier SCaMC-1/SLC25A24 mediates ATP-Mg2−/Pi2− and/or HADP2−/Pi2− uptake into the mitochondria after an increase in cytosolic [Ca2+]. ATP and ADP contribute to Ca2+ buffering in the mitochondrial matrix, resulting in desensitization of the mPT. Comprehensive gene expression analysis showed that SCaMC-1 overexpression is a general feature of transformed and cancer cells. Knockdown of the transporter led to vast reduction of mitochondrial Ca2+ buffering capacity and sensitized cells to mPT-mediated necrotic death triggered by oxidative stress and Ca2+ overload. These findings revealed that SCaMC-1 exerts a negative feedback control between cellular Ca2+ overload and mPT-dependent cell death, suggesting that the carrier might represent a novel target for cancer therapy.

1 July 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
DPDavid Pla-Martín
David Pla-Martín
CRCarlos B. Rueda
Carlos B. Rueda
AEAnna Estela
Anna Estela
MSMaribel Sánchez-Piris
Maribel Sánchez-Piris
PGPaloma González-Sánchez
Paloma González-Sánchez
FPFrancesc Palau
Francesc Palau

1 August 2016 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
CRCarlos B. Rueda
Carlos B. Rueda
ILIrene Llorente-Folch
Irene Llorente-Folch
JTJavier Traba
Javier Traba
IAIgnacio Amigo
Ignacio Amigo
PGPaloma González-Sánchez
Paloma González-Sánchez
JSJorgina Satrustegui
Jorgina Satrustegui